We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry.  By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.

With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.

Bcell Design develops and manufactures chimeric monoclonal antibodies with human-like characteristics for in vitro diagnostics. We provide a secure and reliable source of raw material as a best alternative to disease state plasma and human serum, currently used as calibrators, positive controls, or quality controls. Through its technological platform, built upon 15 years’ expertise in mAb and early-stage immunotherapy development, IVD developers and manufacturers gain access to a wide range of antibodies that are immediately ready for testing in human models.

Bcell Design recently reinforced its industrial capabilities alongside Inoviem Scientific, its major shareholder since the end of 2021, to enlarge the offer of disruptive antibodies development and manufacturing for IVD field.

Our groundbreaking label-free technologies enable you to detect and identify the clinical power of, and weaknesses in, your compound from early-stage pre-clinical R&D through to clinical trials.

Inoviem, a bioanalytical Contract Research Organization (CRO), enables drug developers to gain higher precision in the understanding of a compound’s clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials. Inoviem’s expertise in drug-target interaction analysis is based on its groundbreaking NPOT® and PIMS® label-free technologies. These are the world’s first label-free technologies to decipher the native clinical agent’s proteins and nucleic acids within a physiological environment i.e., directly on non-modified human tissue. This achievement distinguishes Inoviem as a leader in an approach that offers clients new dimensions in identifying the therapeutic effect of pharmacological agents.

Applications:

• Understand the mode of action of your compound
• Validate targets in the study model
• Choose the compound for development
• Stratify different patient groups
• Identify secondary targets
• Validate target in targeted organism
• Define the indication
• Identify biomarkers

Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products for neurodegenerative disorders and cardiovascular diseases. With a comprehensive expertise in the field, Firalis provides an extensive range of biomarker services to support clinical studies & research.

Quanterix™ Corporation is digitizing biomarker analysis with the goal of advancing the science of precision healthcare. Our ultra-sensitive technology platform, Simoa®, enables researchers to quantify a range of disease biomarkers at lower levels than ever before, in most common sample types. Simoa’s ultra-sensitivity, multiplex detection capability and flexibility in custom assay development are advancing both academic research and drug development both in our customers' own facilities and by contract in our CLIA-certified Quanterix Accelerator Laboratory.

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multidimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.